|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: VWA9 |
Gene summary for VWA9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | VWA9 | Gene ID | 81556 |
| Gene name | integrator complex subunit 14 | |
| Gene Alias | C15orf44 | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96SY0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81556 | VWA9 | P31T-E | Human | Esophagus | ESCC | 5.02e-13 | 1.97e-01 | 0.1251 |
| 81556 | VWA9 | P32T-E | Human | Esophagus | ESCC | 3.96e-12 | 2.24e-01 | 0.1666 |
| 81556 | VWA9 | P36T-E | Human | Esophagus | ESCC | 4.54e-15 | 4.23e-01 | 0.1187 |
| 81556 | VWA9 | P37T-E | Human | Esophagus | ESCC | 2.42e-09 | 1.45e-01 | 0.1371 |
| 81556 | VWA9 | P38T-E | Human | Esophagus | ESCC | 2.09e-02 | 9.30e-02 | 0.127 |
| 81556 | VWA9 | P39T-E | Human | Esophagus | ESCC | 3.02e-06 | 1.60e-01 | 0.0894 |
| 81556 | VWA9 | P40T-E | Human | Esophagus | ESCC | 3.86e-03 | 8.51e-02 | 0.109 |
| 81556 | VWA9 | P42T-E | Human | Esophagus | ESCC | 1.41e-16 | 3.10e-01 | 0.1175 |
| 81556 | VWA9 | P44T-E | Human | Esophagus | ESCC | 3.03e-11 | 2.53e-01 | 0.1096 |
| 81556 | VWA9 | P47T-E | Human | Esophagus | ESCC | 7.51e-14 | 2.22e-01 | 0.1067 |
| 81556 | VWA9 | P48T-E | Human | Esophagus | ESCC | 1.58e-05 | 1.64e-01 | 0.0959 |
| 81556 | VWA9 | P49T-E | Human | Esophagus | ESCC | 2.64e-14 | 9.78e-01 | 0.1768 |
| 81556 | VWA9 | P52T-E | Human | Esophagus | ESCC | 1.30e-13 | 3.56e-01 | 0.1555 |
| 81556 | VWA9 | P54T-E | Human | Esophagus | ESCC | 1.18e-08 | 1.39e-01 | 0.0975 |
| 81556 | VWA9 | P56T-E | Human | Esophagus | ESCC | 5.26e-05 | 7.02e-01 | 0.1613 |
| 81556 | VWA9 | P57T-E | Human | Esophagus | ESCC | 7.26e-10 | 2.17e-01 | 0.0926 |
| 81556 | VWA9 | P61T-E | Human | Esophagus | ESCC | 3.48e-14 | 3.64e-01 | 0.099 |
| 81556 | VWA9 | P62T-E | Human | Esophagus | ESCC | 3.28e-17 | 2.10e-01 | 0.1302 |
| 81556 | VWA9 | P65T-E | Human | Esophagus | ESCC | 4.15e-14 | 1.48e-01 | 0.0978 |
| 81556 | VWA9 | P74T-E | Human | Esophagus | ESCC | 3.12e-08 | 3.03e-01 | 0.1479 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |